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The complete amino acid sequence of human plasma apolipoprotein C-III (apoC-III) isolated from normal 
subjects is described. ApoC-III is a linear polypeptide chain of 79 amino acids. Tryptic digestion of intact 
apoC-III produced 5 major peptides, while tryptic digestion of the citraconylated protein yielded two pep- 
tides. The complete amino acid sequence of apoC-III was determined by the automated Edman degradation 
of the intact protein as well as the various tryptic peptides. Phenylthiohydantoin amino acids were identified 
by high-performance liquid chromatography and chemical ionization mass spectrometry. The amino acid 
sequence of apoC-III isolated from normalipidemic subjects is identical to the apoC-III sequence derived 
from the cDNA sequence and differs at 4 positions from the previously reported sequence of apoC-III de- 
rived from a patient with type V hyperlipoproteinemia. 
Amino acid sequence 
1. INTRODUCTION 
The C apolipoproteins, apoC-I, apoC-II and 
apoC-III, are present primarily in the HDL of nor- 
mal subjects and in the chylomicron-VLDL of 
hyperlipoproteinemic patients. These low-M, pro- 
teins have been proposed to have specific physio- 
logical roles in lipoprotein metabolism. ApoC-I 
binds to phospholipids and has been reported to 
increase the activity of lecithin-cholesterol acyl- 
transferase in vitro [ 1,2]. ApoC-II has been shown 
to activate lipoprotein lipase in vitro [3,4] and a 
deficiency of apoC-II is associated with severe 
hypertriglyceridemia [5]. ApoC-III has been pro- 
posed to have an important role in the metabolism 
of triglyceride rich lipoproteins, since it inhibits the 
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Apolipoprotein C-III 
activation of lipoprotein lipase by apoC-II and 
prevents the uptake of lipoproteins containing 
apoE by liver cells [6-lo]. Human apoC-III is a 
glycoprotein and occurs in three isoforms, contain- 
ing 0, 1 or 2 molecules of sialic acid/molecule of 
protein [ 11,121. The primary amino acid sequence 
of apoC-III isolated from a patient with type V 
hyperlipoproteinemia has been reported previously 
and is a linear peptide of 79 amino acids, with a 
carbohydrate moiety attached to the threonine at 
position 74 [13]. Qualitative studies based on elec- 
trophoretic mobility and immunological properties 
suggested that there is no difference between the 
apoC-III from normal individuals and those of pa- 
tients with familial hyperlipoproteinemia [ 121. 
However, the recently reported [14] protein se- 
quence derived from the cDNA sequence for 
apoC-III differs from the amino acid sequence at 
4 positions. The lipid levels of the subjects in this 
study were not reported and is is not clear whether 
the liver used came from normal subjects or a pa- 
tient with hyperlipoproteinemia. We have isolated 
apoC-III from normalipidemic individuals and in 
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this report the complete amino acid sequence of 
normal apoC-III is described. The sequence was 
determined by automated Edman degradation of 
the intact protein, and the tryptic peptides of intact 
and citraconylated apoC-III. 
2. MATERIALS AND METHODS 
The apoC-III used in these studies was isolated 
from the plasma of normalipidemic volunteers. 
The isolation and purification procedures have 
been described in detail [ 121. In brief, HDL or 
VLDL were isolated by preparative ultracen- 
trifugation and delipidated with chloroform- 
methanol (2: 1). The C apolipoproteins were in- 
itially purified on a Sephadex G-200 column in 
0.2 M Tris-HCl in 6 M urea (pH 8.0). The fraction 
containing the C apolipoproteins, as well as the 
different isoforms of apoC-III, was separated on a 
DE-52 (Whatman) column utilizing a linear gra- 
dient of Tris-HCl in 6 M urea (0.01-0.165 M, 
pH 8.0) [12]. ApoC-1111, the isoform containing 
1 mol sialic acid/m01 protein, was used here. 
2.1. Tryptic digestion of apoC-III 
Tryptic peptides were generated by digestion of 
apoC-III with trypsin (Worthington, 100: 1, w/w) 
for 2.5 h at 37°C in 0.2 M ammonium bicarbonate 
(pH 8.5). In a separate study the cleavage of apoC- 
III by trypsin was limited to the arginines by 
modification of apoC-III with citraconic 
anhydride at a lOO-fold excess over the amino 
groups at pH 9.6 followed by cleavage of the 
lysine-modified apoC-III with trypsin (50: 1, w/w) 
for 2.5 h at 37°C. The resultant peptide fragments 
were deblocked by addition of acetic acid 
(pH 3.0). 
2.2. Isolation of peptides 
Tryptic peptides of intact and citraconylated 
apoC-III were separated on reversed-phase HPLC 
using a DuPont 8800 HPLC system and a Waters 
C-18 PBondapack column. The peptides were 
separated by a programmed binary-solvent gra- 
dient system using 0.1% aqueous trifluoroacetic 
acid and acetonitrile as the solvents. The isolated 
peptides wre monitored for purity by amino acid 
analysis (24 h at 108°C in constant boiling HCI) 
using a Beckman 6300 analyzer, thin layer 
chromatography as well as amino-terminal se- 
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quence analysis as described in earlier reports 
[12,13]. 
2.3. Edman degradation 
Intact apoC-III and the isolated tryptic peptides 
were sequenced by automated Edman procedure 
[15] using a modified Beckman 890B sequencer, 
with a 0.1 M quadrol program [ 161. Polybrene was 
used as a carrier in all degradations [ 171. PTH 
derivatives were quantitatively identified by HPLC 
[ 181 on a DuPont-Zorbax ODS column using a Du- 
pont 8800 LC system equipped with a Perkin- 
Elmer Chrom-2 data system and an ISS-100 auto- 
sampler. All PTH derivatives were also identified 
by chemical ionization mass spectrometry using a 
Finnigan 45 10 mass spectrometer and isobutane as 
the reagent gas [19]. 
3. RESULTS 
The amino acid compositions of intact normal 
apoC-III, tryptic as well as citraconylated tryptic 
peptides, are shown in table 1. The amino acid 
composition of the tryptic peptides is identical to 
that of the apoC-III from a hyperlipoproteinemia 
subject previously reported [ 121. 
The complete amino acid sequence of apoC-III 
determined by automated Edman degradation of 
the intact protein and the various tryptic peptides 
is illustrated in fig. 1. The sequence of the initial 43 
residues from the amino-terminal end of the 
molecule was obtained by automated Edman 
degradation of intact apoC-III (fig.1, large ar- 
rows). Serine was identified as the amino-terminal 
residue and the first arginine residue was located at 
step 40 as reported in [13]. Since the amino acid 
composition revealed the presence of 6 lysines and 
2 arginines, as many as 9 peptides would be ex- 
pected from tryptic digestion. However, no 
cleavage occurred at the arginyl-proline bond 
(residues 72-73) and only partial cleavages oc- 
curred at 3 lysine residues (residues 2 1, 24 and 60) 
resulting in only 5 major peptides and 2 
citraconylated tryptic peptides. The presence of 
sialic acid has been reported to influence the extent 
of tryptic cleavage in apoC-III [12,13]. Since the 
small quantities of the 3 short peptides would have 
provided only redundant amino acid sequence in- 
formation, no attempt was made to isolate these 
peptides. The 5 major peptides generated from the 
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Amino acids 
Table 1 
Amino acid composition of native and peptide fragments of normal apoC-III 
ApoC-III TP-1 TP-2 TP-3 TP-4 TP-5 CT-l CT-2 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Proline 
Glycine 
Alanine 
Valine 
~ethionine 
Leucine 
Tytosine 
Phenyialanine 
Histidine 
Lysine 
Arginine 
Tryptophan 
6.95(7) 1.13(l) 
5.01(5) 
10.43(11) 2.86(3) 
9.73(10) 2.75(3) 
2.18(2) 
3.10(3) 1.14(l) 
10.02(10) 1.92(2) 
5.54(6) 
1.83(2) 1.46(2) 
5.20(S) 2.01(2) 
2.14(2) 1.03(l) 
4.09(4) 1.08(l) 
1.00(l) 
6.15(6) 1.07(l) 
1.92(2) 
3.30(3)a 
1.46(l) 
2.12(2) 
2.94(3) 
4.38(5) 
4.67(5) 
l-93(2) 
1*03(l) 
0.91(l) 
2.31(2) 
1*01(l) 
1.17(l) 1.05(l) 
1.03(l) 0.90( 1) 
2.01(2) 1.24(l) 
1.94(2) 
0.94(l) 
1.18(l) 
1.12(l) 
1.01(l) 
ND(l) 
1.03(l) 
0.87( 1) 
0.89( 1) 
ND(l) 
2.59(3) 
1.02(l) 
2.13(2) 
2.15(2) 
1.91(2) 
2.96(3) 
1.84(2) 
1.21(l) 
2.23(2) 
0.79(l) 
0.82(l) 
ND(l) 
2.21(2) 
2.06(2) 
5.38(6) 
7.29(8) 
1.21(l) 
7.24(7) 
2.01(2) 
l-49(2) 
3.31(3) 
1.15(l) 
1.23(l) 
0.98( 1) 
3.05(3) 
0.92( 1) 
4.98(5) 
2.94(3) 
5.07(5) 
2.41(2) 
1.86(2) 
2.34(2) 
3.26(3) 
3.58(4) 
2.31(2) 
1.01(l) 
3.01(3) 
2.98(3) 
0.80( 1) 
ND(l) 
a Determined spectrophotometrically 
All values are expressed as molar ratios of the constituent amino acids following a 24 h hydrolysis at 108°C. Integral 
values in parentheses are numbers of residues/m01 based on sequence data 
TP-2 
_t._ 
T 
TP-4 
55 
TP-5 
Fig. f. The complete amino acid sequence of human plasma apolipoprotein C-III. The large arrows denote automated 
Edman degradations performed on intact apoC-III. The half arrows refer to Edman degradations of isolated tryptic 
peptides and the long arrows indicate the degradations on the tryptic peptides after citraconylation of apoC-III. 
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Fig.2 The elution profile of tryptic peptides on HPLC. 
Bar indicates peptide fraction pooled for sequence 
analysis. A programmable binary-solvent gradient 
system (25-60% acetonitrile) with aqueous trifl uoro- 
acetic acid and acetonitrile as solvents was used for the 
separation of peptides. The peak at 13.6 min was shown 
to be a mixture of TP-1 and TF-5 by sequence analysis. 
tryptic digestion of intact apoC-III were separated 
by HPLC (fig.2). These peptides are designated 
TP-1 (17 amino acids), TP-2 (23 amino acids), 
TP-3 (11 amino acids), TP-4 (7 amino acids) and 
TP-5 (21 amino acids) (table 1). The complete se- 
quences of each of these peptides were obtained as 
follows: 
Peptide TP-1: All 17 residues of TP-1 (50 nmol) 
were determined by automated Edman degrada- 
tion (fig.1). Amino acids l-17 corresponded to 
residues 1-17 of intact apoC-III. Thus, the se- 
quence data established that TP-1 is from the 
amino-terminus of apoC-III. 
Peptide TP-2: The complete sequence of the 23 
residue peptide (90 nmol) revealed that this peptide 
is an overlap tryptic fragment of apoC-111 with in- 
tact lysines at residues 4 and 7 (fig. 1). The relative- 
Iy high yield of this peptide recovered after HPLC 
purification suggested that very little cleavage oc- 
curred at these two Iysine residues and more 
rigorous conditions would be required for com- 
plete cleavage at Iysine residues 4 and 7. The amino 
acid sequence of this peptide corresponded to 
residues 18-40 of the intact apoC-III (fig.1). 
Peptide TP-3: The sequence of this 11 residue 
peptide (35 nmol) was determined by Edman 
degradation. The first 3 amino acids corresponded 
to residues 41-43 of the intact moiecule (fig.1). 
This result indicated that tryptic peptide TP-3 
followed TP-2 in the sequence of apoC-III and 
corresponded to residues 41-5 1. 
Peptide TP-4: Automated Edman degradation 
of peptide TP-4 (25 nmo1) established the sequence 
of this 7 residue peptide. Aspartic acid and Iysine 
were identified as the amino-terminal and carboxy- 
terminal amino acids, respectively (fig. 1). 
Peptide TP-5: The total sequence of the 21 
amino acid peptide (60 nmol) was obtained by Ed- 
man degradation (fig,l). Lysine was identified at 
step 2 and arginine at step 14, indicating that this 
peptide was an overlap tryptic peptide. Since the 
arginine residue is foffowed by a protine, no 
cleavage woufd be expected at the Arg-Pro bond, 
whife the partiaf cfeavage at the Lys-Phe bond is 
attributed to the presence of the siaiic acid contain- 
ing carbohydrate moiety at step 16 [ 133. The 
threonine at step 16 was not identified by HPLC, 
however, it was positively identified as 
dehydrothreonine by mass spectral analysis. Yields 
were reduced at the end of the degradation due to 
the several hydrophobic residues located at the 
carboxy-terminal region of the peptide and the loss 
of peptide from the sequencer cup (fig.1). 
The combined results obtained from the Edman 
degradation of the intact apoC-III and tryptic pep- 
tides TP-i, TP-2, and TP-3 estabfished the com- 
plete amino acid sequence of residues 1-5 1. 
Peptides CT-l and CT-2: To ascertain the align- 
ment of peptides TP-3, TP-4, and TP-5, apoC-III 
was cleaved by trypsin at the arginine residue. 
Specific cleavage at the arginine residues was 
achieved by modification of the lysines by 
citraconylation and tryptic digestion of the 
modified protein. Even though there are two 
arginines in the apoC-III molecule, one arginine 
(residue 14 in peptide TP-5) is not amenable to 
tryptic digestion since it is followed by a proline in 
the sequence. As a result, only two peptides, CT-l 
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(40 amino acids) and CT-2 (39 amino acids) were 
obtained by tryptic digestion of citraconylated 
apoC-III and were separated by HPLC. 
The amino acid sequence of the first 9 residues 
of CT-1 was the same as that of intact apoC-III 
and indicated that this peptide was the amino- 
terminal peptide (fig. 1). The complete sequence of 
peptide CT-2 was determined by automated Ed- 
man degradation (fig.1). Glycine was identified as 
the amino-terminal residue. The first 11 residues 
corresponded to the total sequence of peptide 
TP-3, and residues 12-18 corresponded to the se- 
quence determined for TP-4. These results con- 
firmed the sequence of each peptide and estab- 
lished the alignment of peptides TP-3, TP-4, and 
TP-5 in apoC-III (fig. 1). The threonine at position 
34 in the degradation of peptide CT-2 was iden- 
tified only by mass spectrometry as the 
dehydrothreonine derivative as discussed above. 
The combined results from the Edman degrada- 
tions of intact apoC-III, the tryptic, and 
citraconylated tryptic peptides established the 
complete sequence of normal apoC-III as shown in 
fig. 1. 
205 265 step-15 
TP-2 
PTH-Glutamic 
Acid 
Step 16 
TP-2 
PTH-Swine 
step 14 
TP-2 
PTH-GlutamIne 
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280 320 280 320 200 240 
step 18 
TP-2 
PTH-Val~ne 
step 19 
TP-2 
PTH-Alanine 
‘I step 17 TP-2 
PTH-Glutamine 
235 
L,, II,,,,, .1 
280 320 200 240 
232 
200 240 280 200 240 
loo- 26, 4 step 20 
TP-2 
PTH-Glutamme 
264 step 21 
TP-2 
PTH-Glutamme 
; 207 
I 
step-22 
TP-2 
PTH-Alanme 
I 1 50 I i I I 232 I i 
_&LL ,.j I’ 
280 320 200 240 280 320 280 320 200 240 
m/z 
200 240 
Fig.3’. Identification of phenylthiohydantoin derivatives of apoC-III by chemical ionization mass spectrometry. 
Chemical ionization mass spectra of PTH derivatives (residues 31-39) obtained during the automated Edman degrada- 
tion of tryptic peptide TP-2 (residues 14-22) are illustrated. 
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4. DISCUSSION 
ApoC-III has been shown previously to be a 
glycoprotein containing 1 mol each of galactos- 
amine and galactose/mol protein [ 121. Three poly- 
morphic forms of this protein have been identified 
containing 0, 1 or 2 mol sialic acid/m01 protein 
[ 12,131. The carbohydrate moiety is attached to the 
protein through 0-glycosidic linkage at the 
threonine at position 74 [ 131. 
Human apoC-III isolated from HDL of normal 
individuals is composed of a linear polypeptide 
chain of 79 amino acids with serine as the amino- 
terminal and alanine as the carboxy-terminal 
residue. The amino acid compositions of normal 
apoC-III obtained by acid hydrolysis of the intact 
molecule and the various peptide fragments are in 
complete agreement with the data obtained from 
the amino acid sequence determined by automated 
Edman degradation of intact apoC-III and tryptic 
as well as citraconylated tryptic peptide (fig.1, 
table 1). The threonine residue at position 74, 
which contains the carbohydrate residue was iden- 
tified by mass spectral analysis in peptides TP-5 
and CT-2. 
The amino acid sequence of apoC-III presented 
here differs at 4 positions from the previously 
published sequence for apoC-III, which was 
isolated from a patient with type V hyperlipopro- 
teinemia. These differences occur at positions 32, 
33, 37 and 39 in the sequence. In the previous 
analysis, the amino acids reported at these posi- 
tions were Ser, Gln, Ala and Gin, respectively. 
Here, residue 32 was identified as Glu, residue 33 
as Ser, residue 37 as Gln and residue 39 as Ala. The 
chemical ionization mass spectra of all amino acids 
from residue 31 to 39 (taken from the sequence 
analysis of the tryptic peptide TP-2, residues 
14-22) are illustrated in fig.3. These sequence data 
are in complete agreement with the recently 
reported structure of apoC-III derived from the 
cDNA sequence of human apoC-III [14]. 
It is of interest hat structural variants have been 
reported previously for several other human 
plasma apolipoproteins. Variation in primary 
structure has been reported for apoA-I, and 
designated apOA-IMilano [20-221, apoA-Ioressen 
[231, apoA-IMMarburg 1231 and apoA-IMMunster WI. Pa- 
tients with apOA-IMilano and apoA-IMvlarburg have 
mild hypertriglyceridemia nd reduced levels of 
72 
HDL [20,23]. Polymorphism due to variation in 
the primary structure of apoE has also been 
reported [25-271. In addition, multiple substitu- 
tion of several amino acids has been identified in 
a variant of apoE [28,29]. 
The structural variation in apoC-III in the 
previous study [13] may be of pathophysiological 
importance in the development of hyperlipopro- 
teinemia and further studies will be required to 
identify the occurrence of structural mutants of 
apoC-III in other patients with hyperlipopro- 
teinemia. The elucidation of the primary structure 
of apoC-III derived from normalipidemic subjects 
now enables the chemical synthesis of intact apoC- 
III and its various fragments which may be used to 
analyze the role of apoC-III in modulating lipo- 
protein lipase activity and the effect of structural 
mutants of apoC-III on the hepatic uptake of lipo- 
proteins and the development of dyslipopro- 
teinemias. 
REFERENCES 
[l] Soutar, A.K., Garner, C.W., Baker, H.N., 
Sparrow, J.T., Jackson, R.L., Gotto, A.M. and 
Smith, L.C. (1975) Biochemistry 14, 3057-3064. 
[2] Albers, J.J., Lin, J. and Roberts, C.P. (1979) 
Artery 5, 61-75. 
[3] LaRosa, J.C., Levy, R.I., Herbert, P., Lux, SE. 
and Fredrickson, D.S. (1970) Biochem. Biophys. 
Res. Commun. 41, 57-62. 
[4] Havel, R. J., Shore, J.G., Shore, B. and Bier, D.M. 
(1970) Circ. Res. 27, 597-600. 
[5] Breckenridge, W.C., Little, J.A., Steiner, G., 
Chow, A. and Poapst, M. (1978) N. Engl. J. Med. 
298, 1265-1272. 
[6] Miller, N.E., Rao, S.N., Alaupovic, P., Noble, N., 
Slack, J., Brunzell, J.D. and Lewis, B. (1981) Eur. 
J. Clin. Invest. 11, 69-76. 
[7] Brown, W.V. and Baginsky, M.L. (1972) Biochem. 
Biophys. Res. Commun. 46, 375-381. 
[8] Krauss, R.M., Herbert, P.N., Levy, R.I. and 
Fredrickson, D.S. (1973) Circ. Res. 33, 403-411. 
[9] Windler, E., Chao, Y. and Havel, R. J. (1980) J. 
Biol. Chem. 255, 5473-5480. 
[lo] Kashyap, M.L., Srivastava, L.S., Hynd, B.A., 
Cartside, P. and Perisutti, G. (1981) J. Lipid Res. 
22, 800-810. 
[ll] Albers, J.J. and Scanu, A.M. (1971) Biochim. Bio- 
phys. Acta 236, 29. 
[ 121 Shulman, R.S., Herbert, P.N., Fredrickson, D.S., 
Weherly, K. and Brewer, H.B. jr (1974) J. Biol. 
Chem. 249, 4969-4974. 
Volume 197, number 1,2 FEBS LETTERS March 1986 
1131 Brewer, H.B. jr, Shulman, R., Herbert, P., Ronan, 
R. and Weherly, K. (1974) J. Biol. Chem. 249, 
4915-4984. 
[14] Sharpe, C.R., Sidoli, A., Shelley, C.S., Lucero, 
M.A., Shoulders, C.C. and Baralle, F.E. (1984) 
Nucleic Acids Res. 12, 3917-3932. 
[15] Edman, P. and Begg, G. (1967) Eur. J. Biochem. 
1, 80. 
[16] Fairweh, T. and Brewer, H.B. jr (1979) Anal. Bio- 
them. 99, 242-248. 
[I?‘] Hunkapiller, M.W. and Hood, L.E. (1978) Bio- 
chemistry 17, 2124-2133. 
[18] Zimmerman, C., Pisano, J-J. and Appella, E. 
(1977) Anal. Biochem. 77, 569-573. 
[ 191 Fairwell, T. (1983) Methods Enzymol. 91, 502-5 11. 
[20] Franceschini, G., Sirtori, C.R., Capurso, A., 
Weisgraber, K.N. and Mahley, R.W. (1980) J. 
Clin. Invest. 66, 892-900. 
(211 Weisgraber, K.N., Bersot, T.P., Mahley, R.W., 
Franceschini, G. and Sirtori, C.R. (1980) J. Clin. 
Invest. 66, 901-907. 
[22] Weisgraber, K.N., Rall, S.C., Bersot, T.P., 
Mahley, R.W., Franceschini, G. and Sirtori, C.R. 
(1983) J. Biol. Chem. 258, 2508-2513. 
1231 Utermann, G., Feussner, G., Franceschini, G., 
Maas, J. and Steinmetz, A. (1982) J. Biol. Chem. 
257, 501-507. 
[24] Menzel, M.J., Assmann, G., Rall, S.C., 
Weisgraber, K.N. and Mahley, R.W. (1984) J. 
Biol. Chem. 259, 3070-3076. 
[ZS] Weisgraber, K.N., Rall, S.C. and Mahley, R.W. 
(1981) J. Biol. Chem. 256, 90779083. 
[26] Rall, S.C., Weisgraber, K.N. and Mahley, R. W. 
(1982) J. Biol. Chem. 257, 4171-4178. 
1271 Rail, S.C., Weisgraber, K.N., Innerarity, T.L. and 
Mahley, R.W. (1982) Proc. Natl. Acad. Sci. USA 
79, 4696-4700. 
[28] Rees, A., Shoulders, C.C., Stocks, J., Galton, D.J. 
and Baralle, F.E. (1983) Lancet II, 444-446. 
[29] McLean, J.W., Elshourbagy, N.A., Chang, D.J., 
Mahley, R.W. and Taylor, J.M. (1984) J. Biol. 
Chem. 259, 6498-6504. 
73 
